In a global first, Uganda’s Ministry of Health, the World Health Organization (WHO) and other partners today launched a first-ever clinical efficacy trial for a vaccine from Ebola from the Sudan ...

The FDA has approved Avtozma® (tocilizumab-anoh), a biosimilar to Actemra®, in both intravenous and subcutaneous formulations.

The FDA's approval is grounded in an evidence totality and comprehensive data package, which includes outcomes from a study.

Several therapeutic advances have been achieved over the past two decades for inflammatory bowel disease (IBD). The expanding ...

The biosimilar will be available in both subcutaneous and intravenous formulations and has nearly all the same indications as ...

Immunogenicity was assessed by hemagglutination-inhibition (HI) prevaccination and 28 days after each vaccination. Immunogenic non-inferiority QIV versus TIV for shared strains, and superiority ...

Operator Good day, everyone and welcome to Pfizer's fourth-quarter 2024 earnings conference call. Today's call is being ...

The biosimilar's safety and immunogenicity profiles were found to be comparable to those of the reference product in the ...

In what looks like a global first, Uganda’s Ministry of Health, the World Health Organisation (WHO) and other partners on ...